Vaccine given post-exposure protects monkeys against deadly Mar...( WHAT: Marburg haemorrhagic fever is a...),Health

WHAT: Marburg haemorrhagic fever is an uncommon disease. In some outbreaks in Africa, nearly 90 percent of cases have been fatal. Such high mortality rates make Marburg virus, the agent that causes the disease, a great concern for researchers developing medical countermeasures against potential bioterrorist threats. Currently there is no effective way to prevent or treat Marburg virus after someone is infected, but new research appearing in this week's issue of the journal The Lancet may change that. A study by a group of U.S. and Canadian researchers has revealed that a vaccine made from an attenuated recombinant vesicular stomatitis virus (rVSV) and administered to five rhesus macaques 20 to 30 minutes after exposure to a high dose of Marburg virus helped all of them survive. Three control monkeys not protected with the vaccine all died within two weeks. This result demonstrates that it may be possible to use rVSV vaccines to treat Marburg and similar viruses, such as Ebola, after infection. Studies are now in progress to determine how late after exposure these vaccines might be beneficial.

ARTICLE: "Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment," by KM Daddario-DiCaprio et al. The Lancet DOI: 10.1016/S0140-6736(06)68546-2 (2006). This study was conducted by scientists at the Uniformed Services University of Health Sciences; the U.S. Army Medical Research Institute of Infectious Diseases; the Public Health Agency of Canada; the University of Manitoba; and the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health.

SPOKESPERSON: Peter B. Jahrling, Ph.D., Chief Scientist, NIAID Integrated Research Facility at Fort Detrick in Frederick, Maryland, is available to comment on the study's findings.

'"/>

Contact: Jason Bardi
jbardi@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Apr-2006

Page: 1
Related medicine news :

1. Health officials renew Indo-US Vaccine Action Program
2. International AIDS Vaccine Initiative statement on male circumcision
3. Vaccine for brain tumors shows promising results
4. International AIDS Vaccine Initiative calls for new measures to search for an AIDS vaccine
5. Vaccine could be effective after exposure to Marburg virus
6. Vaccine for follicular lymphoma
7. Vaccine may protect babies from lethal infection
8. NIAID funds Center for HIV/AIDS Vaccine Immunology (CHAVI)
9. Vaccine against cervical cancer and genital warts shows promise
10. Support for Childrens Health and Medicare Protection Act given to House leaders by ACP
11. Experts call for urgent research into anti-epileptic drugs given to children